Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center.
Saved in:
| Title: | Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center. |
|---|---|
| Authors: | Meyerhardt JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America., Yue H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States of America.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States of America., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States of America.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States of America., Brais L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America., Ma C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America., Johnson S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America., Harrod J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America., Burman SSR; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States of America.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States of America., Hendrickson LM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America., Fischinger S; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States of America., Alter G; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States of America., Hahn W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States of America.; Broad Institute of Harvard and MIT, Cambridge, MA, United States of America., Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States of America.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States of America. |
| Source: | PloS one [PLoS One] 2022 Apr 12; Vol. 17 (4), pp. e0266791. Date of Electronic Publication: 2022 Apr 12 (Print Publication: 2022). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
